Xeris (XERS) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool.

DATE

Thursday, Aug. 6, 2026 astatine 8:30 a.m. ET

CALL PARTICIPANTS

• Senior Vice President of Investor Relations - Allison Wey

• Chairman and Chief Executive Officer - John Shannon

• Chief Financial Officer - Steven Pieper

Full Conference Call Transcript

Operator: Hello everyone, convey you for joining america and invited to Xeris Biopharma Second Quarter Earnings Conference Call. [Operator Instructions] I volition present manus the league implicit to Allison Wey, Senior Vice President of Investor Relations. Allison, delight spell ahead.

Allison Wey: Thank you, Leah. Good greeting everyone and invited to Xeris Biopharma Second Quarter Financial Results Conference. Early this morning, we issued a property merchandise detailing our results. This property merchandise tin beryllium recovered connected our website. Joining maine connected today's telephone is John Shannon, our Chairman and Chief Executive Officer; and Steve Pieper, our Chief Financial Officer. Following our prepared remarks, we'll unfastened the telephone for your questions. Before we begin, I'd similar to punctual you that today's treatment volition see forward-looking statements regarding Xeris' aboriginal expectations, plans, strategies, objectives, and fiscal performance.

These forward-looking statements are based connected management's existent assumptions and beliefs and are taxable to a fig of risks and uncertainties that could origin existent results to disagree materially from those expressed oregon implied. For treatment of these risks and uncertainties, delight notation to the hazard factors described successful our filings with the SEC. Any forward-looking statements made connected this telephone talk lone arsenic of today's date, and but arsenic required by law, the institution undertakes nary work to update oregon revise these statements. In addition, during today's call, we volition notation definite fiscal measures that are presented connected a non-GAAP basis.

A reconciliation of these non-GAAP measures to the astir straight comparable GAAP measures is included successful our net release. And with that, I'll crook the telephone implicit to John.

John Shannon: Thank you, Allison, and bully morning, everyone. The 2nd 4th was different record-breaking 4th for Xeris, 1 that demonstrated erstwhile again that the commercialized momentum we person built is durable and accelerating. Total gross reached $92 cardinal with nett merchandise gross of $91 million, representing 34% maturation year-over-year. Recorlev led the mode with 81% growth, Keveyis delivered different 4th of steady, reliable performance, and Gvoke improved sequentially, arsenic we expected. But the 2nd 4th was much than a commercialized story. It was a 4th of meaningful strategical progress. We made important strides successful strengthening our intelligence spot portfolio crossed some our commercialized franchise and our pipeline.